The program targets researchers with strong AI/ML expertise and interest in accelerating scientific discovery, which aligns with the venture's use of protein language models for drug resistance prediction. However, it is a fellowship requiring on-site collaboration and does not provide direct funding or equity, and the founder's profile (pharmacist-turned-ML engineer, not a current PhD student) may not perfectly match the ideal candidate criteria.